Conference Reports for NATAP

Back

14th International Workshop on Clinical Pharmacology of HIV Therapy April 22-24, 2013 Amsterdam     Clinical Pharmacology at the 14th Workshop on Clinical Pharmacology of HIV Therapy and HCV - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center - (05/20/13)   Pharmacokinetics, Metabolism and Excretion of Tenofovir Alafenamide (TAF) - (06/11/13)   Evaluation of the Drug Interaction Potential Between the Pharmacokinetic Enhancer Cobicistat and Tenofovir Disoproxil Fumarate in Healthy Subjects - (06/11/13)   Clinical Pharmacology Workshop in HIV (and HCV) Presentations on New DAAs (oral HCV drugs in phase 3 development now) by Boehringer Ingelheim, Gilead & BMS, by Janssen for telaprevir - (05/31/13)   Maraviroc, Boceprevir, Telaprevir PK in Healthy Volunteers: The effect of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers - (05/26/13)   Dolutegravir, Boceprevir, Telaprevir PK: The effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics, in Healthy Adult Subjects - (05/26/13)   Pharmacokinetic (PK) interactions between Boceprevir (BOC) and Atazanavir/r (ATV/r) or Raltegravir (RAL) in HIV/HCV coinfected patients (pts) - (05/26/13)   Cerebrospinal Fluid Concentrations Above Drugs IC95s are Associated With CSF Viral Loads Below 50 copies/ml - (05/26/13)   Total and Unbound Darunavir (DRV) Pharmacokinetics (PK) in HIV-1-Infected Pregnant Women - (05/26/13)   Establishing darunavir dosing recommendations in treatment-naïve and treatment-experienced pediatric patients - (05/26/13)   Pharmacokinetics and Pharmacodynamics of Once-Daily Etravirine and Darunavir/Ritonavir in Early Treatment-Experienced Subjects - (05/26/13)   Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents in healthy volunteers - (05/26/13)   Pharmacokinetics, Metabolism and Excretion of Tenofovir Alafenamide (TAF) - (05/26/13)   Evaluation of the Drug Interaction Potential Between the Pharmacokinetic Enhancer Cobicistat and Tenofovir Disoproxil Fumarate in Healthy Subjects - (05/26/13)   Darunavir Dosing Determined for Naive and Experienced Children and Teens - written by Mark Mascolini - (04/29/13)   No Clinically Significant Interactions Between Boceprevir or Telaprevir and Dolutegravir - written by Mark Mascolini - (04/29/13)   Protease Inhibitors Boost Levels of Cenicriviroc, a CCR5/CCR2 Antagonist - written by Mark Mascolini - (04/29/13)   Ribavirin Trough Affects Early HCV Response With Unfavorable IL28B Profile - written by Mark Mascolini - (04/29/13)   Once-Daily Etravirine Plus Darunavir/Ritonavir With No NRTIs: 48-Week PKs - written by Mark Mascolini - (04/25/13)   Tenofovir Exposure Moderately Higher With vs Without Cobicistat in Healthy Volunteers - written by Mark Mascolini - (04/25/13)   Ribavirin Levels 50% Higher With Than Without Telaprevir - written by Mark Mascolini - (04/24/13)   Split Dosing Versus Single Dose of Long-Acting Injected Integrase Inhibitor - written by Mark Mascolini - (04/24/13)   Gender and Weight Affect Long-Acting Rilpivirine Levels in Healthy Volunteers - written by Mark Mascolini - (04/24/13)   Labs Inaccurate in 18% of Darunavir, Etravirine, or Raltegravir Measures - written by Mark Mascolini - (04/23/13)   Variable Boceprevir Impact on Levels of Atazanavir and Raltegravir - written by Mark Mascolini - (04/23/13)   Higher Maraviroc Levels With HCV Agents Boceprevir and Telaprevir - written by Mark Mascolini - (04/23/13)   In-Hospital Antiretroviral Prescribing Errors Common and Often Uncorrected - written by Mark Mascolini - (04/23/13)